In a trial matching new treatments to cancer patients based on the genetic makeup of their tumors, the tumors shrank in 22% of the patients treated with the AKT inhibitor drug ipatasertib. This included patients with breast cancer and endometrial cancer as well as two rarer forms—anal and salivary gland. In the majority of the other patients (56%) their cancer remained stable, meaning their tumors neither shrank nor grew.
from Medical Xpress - latest medical and health news stories https://ift.tt/aw6yTSG
